A new drug lead for Naegleria infection and visceral leishmaniasis

Corifungin, a natural product discovered and produced by Acea Pharmaceuticals, was shown by CDIPD investigators Dr. Geraldine DeMuylder and Dr. Anjan Debnath to have efficacy against Naegleria fowleri, the causative agents of primary amoebic meningal encephalitis, and Leishmania donovani, the parasite responsible for visceral leishmaniasis. CDIPD is collaborating with the Acea Pharmaceuticals to seek funding from NIAID for preclinical testing. Corifungin has received Orphan Drug Status from the FDA.